Androgen receptors bind to male hormones called androgens. Females also produce small amounts of androgens. About 70% of estrogen receptor-positive (ER+) breast cancers and about 40% of triple-negative breast cancers (TNBC) express androgen receptors.
Research has shown that androgen receptors play a role in breast cancer cell growth. Therefore, drugs that target the androgen receptor are being studied in clinical trials as treatments for people with breast cancer, including MBC. These drugs are also being tested to overcome resistance to hormone therapy and CDK4/6 inhibitors.
Read below to learn more about research into drugs that target androgen receptors in MBC and find clinical trials for androgen receptor-positive breast cancer.
Drugs Targeting Androgen Receptors
- Susan G. Komen: Drugs that target the androgen receptor are being tested to treat MBC (scroll to “Selective androgen receptor agonists”)
Androgen Receptors in TNBC
- Dr. Liz O’Riordan (video): Targeting androgen receptors in TNBC may be an effective treatment strategy
Androgen Receptors in ER+ MBC
- Genetic Engineering & Biotechnology News: Targeting androgen receptors in ER+ MBC may help overcome resistance to hormone therapy
- Practice Update: The androgen receptor modulator, enobosarm, is being tested in people with androgen receptor-positive, ER+ MBC
MBC Clinical Trials
- Metastatic Trial Search: Trials for Androgen Receptor Positive (AR+) MBC
- Metastatic Trial Search: Trials Studying Androgen Receptor Inhibitors
Last Modified on April 1, 2024